Hengrui, Zhengda Tianqing anti-tumor drug price negotiation succeeded! Will the sales of androtinib exceed 1 billion this year?

As the only two local enterprises shortlisted, aiyang and fukewei are successfully included in the medical insurance For Hengrui and Zhengda Tianqing, it undoubtedly provides a strong guarantee for the large quantity of future products in the market On September 25, according to the financial Associated Press, in the 2018 special negotiation on the access of anticancer drugs to medical insurance led by the National Health Insurance Bureau, two domestic varieties, namely, Zhengda Tianqing's anluotini hydrochloride capsule (focovi) and Hengrui's peimendong enzyme injection (aiyang), were successfully negotiated and will be included in the medical insurance catalogue, which is also the only two domestic products in the negotiation 18 products from 12 enterprises were shortlisted in the special negotiation on the access of anticancer drugs to medical insurance It is reported that the medical insurance bureau and the enterprise have completed the most important negotiation work (bargaining) on 15th of this month, and signed an agreement It is expected that the National Medical Insurance Bureau will soon announce the specific results of the negotiation According to e drug managers, compared with the last negotiation, it is easier to reach consensus on the process and mutual expectations in this round Therefore, it is understood that the number of exits this time is not large, or even not Moreover, due to the experience of the last round of negotiation, the price reduction range of this round can be expected In May 2016, kemina, a domestic anti-cancer drug under Beida for the treatment of non-small cell lung cancer, became the only domestic new drug shortlisted in the first round of national health insurance price negotiation, with the final price reduction of 54%; in 2017, the price of 17 anti-cancer drugs included in the medical insurance was also significantly reduced, with an average reduction of 57% As the only two local enterprises shortlisted, aiyang and fukewei are successfully included in the medical insurance For Hengrui and Zhengda Tianqing, it undoubtedly provides a strong guarantee for the large quantity of future products in the market Although the price of the products has been greatly reduced, for the anticancer drugs entering the catalogue, the National Medical Security Bureau has required to do a good job in the provincial-level centralized purchase of anticancer drugs, and carry out the relevant guarantee in terms of access and quantity Therefore, if the negotiation is successful, the speed of volume production will be faster than before Previously, the industry circulated a "notice on holding a seminar on the special procurement of imported anticancer drugs of the inter provincial alliance" issued by Shaanxi health and Family Planning Commission According to the notice, 12 provinces, including Shaanxi, Inner Mongolia and Ningxia, held meetings to discuss issues related to the special procurement of imported anti-cancer drugs This means that the regional alliance officially launched the "bargain" of imported drugs, and the anti-cancer drugs ushered in a new wave of price cuts In addition, according to the previous two rounds of drug price negotiations, many provinces and cities have accounted for the negotiated varieties separately and not included them in the hospital drug proportion assessment Therefore, from the national level, we should not only vigorously promote drug price negotiations, but also make the enterprises involved in drug price negotiations profitable, so as to provide various favorable guarantees for the implementation of the policy Hengrui: we are looking forward to the approval of peimendong enzyme injection (aiyang) in 2009 It has been widely used in the treatment of acute lymphoblastic leukemia and malignant lymphoma It is reported that acute lymphoblastic leukemia incidence rate is higher in children and adolescents, accounting for 76% of children under 15 years old Compared with the shortlisted fokewei of Zhengda Tianqing, Hengrui's Pegaspargase Injection has been a mature product for nearly 10 years According to the data, due to the recognition of clinical application, the domestic sales of Pei asparaginase continued to grow rapidly From 2012 to 2017, the 5-year compound growth rate of Pei asparaginase exceeded 20% At the beginning of 2017, aiyang was included in the Shandong serious illness medical insurance catalogue, and obtained local medical insurance payment support And this time into the national health insurance catalog, is bound to boost AI Yang further in the market volume In 2017, apatinib, a national class 1.1 new drug independently developed by Hengrui, entered the national medical insurance catalogue through negotiation, with an average decrease of about 37% compared with the original price According to the 2017 financial report of Hengrui, apatini's annual production increased by 67.83% year on year, and its annual sales increased by 73.55% year on year At present, in the domestic market, there is no other competitive product of peimendong enzyme injection produced by Hengrui Therefore, on the one hand, the high price products with high market share will be substantially reduced through negotiation, so that more patients can use drugs; on the other hand, for enterprises, the way of price for quantity will continue to consolidate the market position of products In terms of marketing, Hengrui is no inferior Since 2017, Hengrui's sales system has started a major change First of all, on the basis of the original sales model, the structure of the sales product line is refined, and the important businesses or products are subdivided It is understood that at present, all products of Hengrui have been divided into 5 sales pipelines according to the indication field, namely anti-tumor, imaging, anesthesia, chronic disease and comprehensive product lines Secondly, Hengrui is further expanding its sales team In 2017, Hengrui has expanded its scale to about 10000 people on the basis of more than 7200 people in the previous year According to Hengrui's 2017 annual report, after the adjustment of the distribution line, its sales staff has increased by 2200 net, which has formed a professional sales team of academic and professional promotion BOC Securities believes that in the long run, access to the periodic catalogue of cancer drugs and high priced drugs and spiral price reduction may become the norm Cross regional joint centralized procurement will also become an important means of negotiation and price reduction For the R & D enterprises of anticancer drugs, the irreplaceable varieties and effective marketing will become the core competitiveness of enterprises Zhengda Tianqing: take the lead In June this year, the Chinese biopharmaceutical subsidiary, Zhengda Tianqing, independently developed the anti-small cell lung cancer drug androtinib, which was approved for listing At the same time, it is the only domestic innovative drug in this round of anti-cancer drugs included in the medical insurance negotiation Enrotinib is the first innovative small molecule drug developed by Zhengda Tianqing in accordance with the international R & D process and standards, and it is also the anti-cancer drug with the largest R & D investment so far In this round of negotiation on anticancer drugs, there are 5 products for the treatment of non-small cell lung cancer In addition to Zhengda Tianqing, Pfizer, AstraZeneca, Bi and Novartis are all listed In the first round of drug price negotiation, Kemena, a non-small cell lung cancer treatment product owned by Beida, and yiruisha of AstraZeneca, decreased by more than 50%, and maintained the outstanding performance of product sales For Zhengda Tianqing, as a class 1.1 new drug developed independently, it is not known whether androtinib, like Kemena, can finally achieve the result of price for quantity The first indication of arotinib is the three-line treatment of advanced non-small cell lung cancer In fact, the three-line treatment drugs are not clearly defined in clinical practice Chemotherapy, anti angiogenesis and tumor immunotherapy are all direct or indirect competitors In addition, the survival time of patients with advanced lung cancer is relatively short For example, the pre-treatment has a great impact on physical strength score or the patients' economic capacity consumption is too large, which will make the target patients of the third-line treatment far less than the first-line and second-line treatment, which may have an impact on the growth of androtinib Of course, from the present point of view, the performance of androtini is very eye-catching According to the news, since its launch in June, the volume of androtinib has exceeded the market expectation So far, the sales volume has reached RMB 560 million, and it is expected to become the fastest innovative drug in China After being successfully included in the medical insurance catalogue, the market volume of androtinib will be faster Obviously, a strong sales network guarantees the outstanding performance of the company after its IPO As the holding parent company of Zhengda Tianqing, China's biopharmaceutical sales network spreads all over the country, with more than 12000 professional academic promotion personnel, cooperating with more than 6000 domestic hospitals, covering 90% of the second-class and above hospitals nationwide Although most of the core products in the past were generic drugs, with its strong sales ability, it did not lose the edge in the competition of expanding market share It can not only maintain its strength in its own strong field, but also achieve a large amount of products to gain share in the field that it is not good at This is the embodiment of China's biopharmaceutical sales strength, and it also provides strong support for the rapid volume of innovative drugs such as androtinib In addition, in addition to non-small cell lung cancer, arotinib is also expanding the scope of indications The clinical trial of androtinib in soft tissue sarcoma in the United States has entered clinical phase III indications such as medullary thyroid cancer, metastatic colorectal cancer and gastric cancer in China will be gradually declared, with the effect of anti-cancer drug price negotiation According to CITIC Securities Analysis, the sales volume of androtinib is expected to continue to exceed the market expectation, and the peak sales volume is expected to exceed 4 billion yuan.